Targeted Biopsy May Reclassify Prostate Cancer

Share this content:
Targeted Biopsy May Reclassify Prostate Cancer
Targeted Biopsy May Reclassify Prostate Cancer

(HealthDay News) -- Targeted prostate biopsy using multi-parametric magnetic resonance imaging-ultrasound fusion (mpMRI-US) may lead to reclassification of prostate cancer that was initially diagnosed as low-risk, according to research published in The Journal of Urology.

Jim C. Hu, MD, MPH, of the David Geffen School of Medicine at the University of California Los Angeles, and colleagues identified 113 men (median age, 64 years; prostate-specific antigen, 4.2 ng/mL; prostate volume, 46.8 cc) under active surveillance for low-risk prostate cancer. The patients subsequently received confirmatory, targeted biopsy using mpMRI-US.

RELATED: Male Reproductive Cancers Resource Center

The researchers found that confirmatory fusion biopsy led to reclassification of prostate cancer in 41 men (36%), including 26 men (23%) with Gleason grade greater than 6 and 15 men (13%) with high-volume Gleason grade 6 disease. 

According to stratification by suspicion on mpMRI, the probability of reclassification was 24% to 29% for target grade 0 to 3, 45% for target grade 4, and 100% for target grade 5 (P=0.001). 

Men with prostate cancer that was grade 4 or 5, compared with lower target grades, were greater than three times more likely to have their disease reclassified (odds ratio, 3.2; 95% confidence interval, 1.4 to 7.1; P=0.006).

"Upon confirmatory re-biopsy using mpMRI-US, men with high-suspicion mpMRI targets were frequently reclassified (45% to 100%," the researchers wrote.

Reference

  1. Hu JC, Chang E, Natarajan S, et al. Targeted Prostate Biopsy to Select Men for Active Surveillance: Do the Epstein Criteria Still Apply? J Urol. 2014;doi:10.1016/j.juro.2014.02.005.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs